AVITA Medical, Inc.
FAIR PRICE VALUATION
Updated daily
Model: DCF 50% · Relative 30% · Consensus 20%
MARKET PRICE
$4.12
FAIR PRICE
$3.64
MARGIN
$0.48
P/E Ratio
N/A
Div. Yield
N/A
ROE
476.6%
Exceptional
Market Cap
$102M
Small-cap
NOW AVAILABLE
Get notified when RCEL's fair price changes
Push notifications when RCEL's valuation shifts. Available on iOS and Android.
FPI RATING
Consistent growth trajectory and attractive valuation, but volatile earnings pattern.
Analytical data, not an investment recommendation. Updated daily.
How we calculate this ↗MARGIN OF SAFETY
A 20% margin of safety below fair value — the conservative entry level for risk-aware investors.
SAFETY MARGIN
20%
Below fair value
ENTRY LEVEL
$2.91
Fair price × 0.80
DISTANCE
29.3%
Price to entry level
At the current price of $4.12, RCEL trades 29.3% above the conservative entry level of $2.91. This entry level represents a 20% margin of safety below the calculated fair price of $3.64 — a buffer that accounts for estimation uncertainty in the valuation model.
Margin of safety is a risk management concept, not an investment recommendation. The 20% threshold follows Benjamin Graham's value investing framework. Fair price and entry levels are model-based estimates updated daily. Learn more about Margin of Safety ↗
VALUATION HISTORY
Loading chart data...
P/E RATIO HISTORY
Loading chart data...
METHODOLOGY
How we calculate RCEL's fair price
AVITA Medical, Inc.'s fair price of $3.64 is derived from a blended model that combines DCF analysis (50%), relative valuation against Healthcare peers using metrics like P/E and EV/EBITDA (30%), and analyst consensus (20%). At the current market price of $4.12, RCEL trades 11.7% above its calculated fair value.
DCF MODEL · 50%
Discounted free cash flow analysis based on projected cash flows, discounted at a rate reflecting RCEL's risk profile.
RELATIVE · 30%
Comparing RCEL's valuation multiples against Healthcare peers to determine if the stock is over or undervalued relative to its industry.
ANALYST · 20%
Aggregated analyst price targets for RCEL, weighted by recency and analyst accuracy.
TRY IT YOURSELF
Want to test your own assumptions? Use our free calculators to estimate RCEL's fair value with your own inputs.
LEARN MORE
POWERED BY BULIOS
Get full analysis, financials, and AI insights for RCEL.
Explore on BuliosFAQ
What is the fair price of RCEL?+
Based on our blended model combining DCF analysis (50%), relative valuation against Healthcare peers (30%), and analyst consensus (20%), the fair price for AVITA Medical, Inc. is $3.64. At the current market price of $4.12, RCEL trades 11.7% above its calculated fair value.
Is RCEL overvalued or undervalued?+
AVITA Medical, Inc. is currently overvalued based on our valuation model. The stock trades at $4.12, which is 11.7% above the fair price of $3.64.
What is the margin of safety for RCEL?+
With a 20% margin of safety applied to the fair price of $3.64, the conservative entry level for RCEL is $2.91. At the current market price of $4.12, the stock trades 29.3% above this entry level. Margin of safety is a risk management concept from Benjamin Graham's value investing framework, not an investment recommendation.
How often is RCEL's fair price updated?+
We update fair price calculations for RCEL daily after market close. The current fair price of $3.64 incorporates the latest market data and sector multiples.
What factors affect RCEL's fair price calculation?+
RCEL's fair price of $3.64 is derived from DCF analysis (50% weight), relative valuation against Healthcare peers (30% weight), and analyst consensus (20% weight)., ROE of 476.6%.
Is RCEL a good buy right now?+
At $4.12, RCEL trades 11.7% above our fair value estimate of $3.64. The stock is currently overvalued. ROE stands at 476.6% (exceptional). Fair Price Index provides valuation data — always do your own research before investing.
Does RCEL pay dividends?+
RCEL does not currently pay a dividend.
RELATED STOCKS
Fair Price Index is for informational purposes only and does not constitute investment advice. Fair value calculations are model-based estimates and may not reflect actual market conditions. Always conduct your own research before making investment decisions.